DK3067066T3 - Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom - Google Patents

Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom Download PDF

Info

Publication number
DK3067066T3
DK3067066T3 DK16154617.1T DK16154617T DK3067066T3 DK 3067066 T3 DK3067066 T3 DK 3067066T3 DK 16154617 T DK16154617 T DK 16154617T DK 3067066 T3 DK3067066 T3 DK 3067066T3
Authority
DK
Denmark
Prior art keywords
synucleinopatic
prevention
treatment
amyloidogenic disease
amyloidogenic
Prior art date
Application number
DK16154617.1T
Other languages
Danish (da)
English (en)
Inventor
Dale B Schenk
Eliezer Masliah
Manuel J Buttini
Tamie J Chilcote
Edward Rockenstein
Kate Dora Games
Original Assignee
Prothena Biosciences Ltd
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/710,248 external-priority patent/US9034337B2/en
Priority claimed from US11/697,646 external-priority patent/US20080014194A1/en
Application filed by Prothena Biosciences Ltd, Univ California filed Critical Prothena Biosciences Ltd
Application granted granted Critical
Publication of DK3067066T3 publication Critical patent/DK3067066T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/80—Immunoglobulins specific features remaining in the (producing) cell, i.e. intracellular antibodies or intrabodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK16154617.1T 2007-02-23 2008-02-22 Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom DK3067066T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/710,248 US9034337B2 (en) 2003-10-31 2007-02-23 Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US11/697,646 US20080014194A1 (en) 2003-10-31 2007-04-06 Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US98472107P 2007-11-01 2007-11-01
EP12188562.8A EP2583978B1 (en) 2007-02-23 2008-02-22 Prevention and treatment of synucleinopathic and amyloidogenic disease

Publications (1)

Publication Number Publication Date
DK3067066T3 true DK3067066T3 (da) 2019-05-20

Family

ID=39710678

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16154617.1T DK3067066T3 (da) 2007-02-23 2008-02-22 Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom

Country Status (7)

Country Link
US (1) US8092801B2 (enExample)
EP (2) EP2118300B1 (enExample)
JP (1) JP5558834B2 (enExample)
CA (1) CA2678963C (enExample)
DK (1) DK3067066T3 (enExample)
PL (2) PL2118300T3 (enExample)
WO (1) WO2008103472A2 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
PL2426143T3 (pl) 2007-01-05 2017-12-29 University Of Zurich Sposób zapewniania specyficznych wobec choroby cząsteczek wiążących i celów
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
JP5558834B2 (ja) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
AU2015249034B2 (en) * 2007-12-28 2017-07-27 Prothena Biosciences Limited Treatment and prophylaxis of amyloidosis
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
NZ589302A (en) 2008-04-17 2012-11-30 Declion Pharmaceuticals Inc Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
JP5747414B2 (ja) 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
DK2370466T3 (en) 2008-12-19 2015-08-03 Univ Zuerich Humane anti-alpha-synuclein-autoantistoffer
JP6126009B2 (ja) 2010-11-17 2017-05-10 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． α−シヌクレイン発現の調節
CA2839563C (en) 2011-06-23 2019-10-29 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
KR101600733B1 (ko) 2011-10-28 2016-03-09 프로테나 바이오사이언시즈 리미티드 알파-시누클레인을 인식하는 인간화된 항체
JP6342333B2 (ja) 2012-01-27 2018-06-13 プロセナ バイオサイエンシーズ リミテッド α−シヌクレインを認識するヒト化抗体
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
CA2902026C (en) 2013-03-13 2023-08-29 Prothena Biosciences Limited Tau immunotherapy
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
EP3071974A2 (en) * 2013-11-19 2016-09-28 Prothena Biosciences Limited Monitoring immunotherapy of lewy body disease from constipation symptoms
AU2014351996B2 (en) * 2013-11-21 2020-01-02 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2015179867A1 (en) * 2014-05-23 2015-11-26 University Of South Florida Methods, antibodies, and vaccines utilizing epitopes of alpha synuclein for treatment of parkinson's disease
WO2016061389A2 (en) 2014-10-16 2016-04-21 Genentech, Inc. Anti-alpha-synuclein antibodies and methods of use
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
US20160251417A1 (en) * 2015-01-22 2016-09-01 Prothena Biosciences Limited Antibodies recognizing medin
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
MX2018013384A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
CN109415434B (zh) 2016-05-02 2022-12-30 普罗塞纳生物科学有限公司 识别tau的抗体
KR102506091B1 (ko) 2016-05-02 2023-03-07 프로테나 바이오사이언시즈 리미티드 타우 면역요법
TW202309093A (zh) * 2016-06-02 2023-03-01 英商梅迪繆思有限公司 針對α-突觸核蛋白之抗體及其用途
US11725232B2 (en) 2016-10-31 2023-08-15 The Hong Kong University Of Science And Technology Compositions, methods and kits for detection of genetic variants for alzheimer's disease
AR110074A1 (es) * 2016-11-15 2019-02-20 H Lundbeck As Agentes, usos y métodos para el tratamiento de la sinucleinopatía
US11237176B2 (en) * 2016-12-02 2022-02-01 Prothena Biosciences Limited Infrared assay detecting secondary structure profiles of alpha-synuclein
JP7144755B2 (ja) 2016-12-16 2022-09-30 ハー・ルンドベック・アクチエゼルスカベット 薬剤、使用および方法
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
IL270361B2 (en) * 2017-05-01 2025-04-01 Univ Pennsylvania Monoclonal antibodies against alpha-synuclein fibrils
WO2018204546A2 (en) 2017-05-02 2018-11-08 Prothena Biosciences Limited Antibodies recognizing tau
EP3406632A1 (en) 2017-05-23 2018-11-28 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati Ligands binding to prion protein for use in the treatment of synucleinopathies
DK3672631T5 (da) 2017-08-22 2024-08-26 Biogen Ma Inc Farmaceutiske sammensætninger indeholdende anti-beta-amyloid-antistoffer
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
CA3088112A1 (en) 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
MX2020007439A (es) 2018-01-12 2020-09-14 Bristol Myers Squibb Co Oligonucleotidos antisentido que actuan sobre alfa-sinucleina y usos de estos.
JP7525474B2 (ja) * 2018-08-09 2024-07-30 エフ． ホフマン－ラ ロシュ アーゲー パーキンソン病の判定
PE20211777A1 (es) 2018-11-08 2021-09-08 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CA3131531A1 (en) 2019-03-03 2020-09-10 Prothena Biosciences Limited Antibodies recognizing tau
MX2022013173A (es) 2020-04-24 2022-11-30 Hoffmann La Roche Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados.
US20230365665A1 (en) 2020-09-17 2023-11-16 Qatar Foundation For Education, Science And Community Development ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED a-SYNUCLEIN AGGREGATES
CA3192429A1 (en) * 2020-09-17 2022-03-24 Robin Barbour Alpha-synuclein vaccine for the treatment of synucleinopathies

Family Cites Families (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
US5208036A (en) 1985-01-07 1993-05-04 Syntex (U.S.A.) Inc. N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4666829A (en) 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US4883666A (en) 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US6093406A (en) 1988-06-02 2000-07-25 The United States Of America As Represented By The Secretary Of The Army Vaccine for induction of immunity to malaria
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5576184A (en) 1988-09-06 1996-11-19 Xoma Corporation Production of chimeric mouse-human antibodies with specificity to human tumor antigens
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE68907045T2 (de) 1989-01-17 1993-12-02 Eniricerche Spa Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind.
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
DK0710719T3 (da) 1990-01-12 2007-07-09 Amgen Fremont Inc Frembringelse af xenogene antistoffer
US5279833A (en) 1990-04-04 1994-01-18 Yale University Liposomal transfection of nucleic acids into animal cells
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5753624A (en) 1990-04-27 1998-05-19 Milkhaus Laboratory, Inc. Materials and methods for treatment of plaquing disease
JP2980677B2 (ja) 1990-04-27 1999-11-22 マクマイケル，ジョン 不正常なアミロイドβタンパク質と関連する中枢神経系疾患状態の治療のための方法および組成物
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018980A1 (en) 1990-06-01 1991-12-12 Cetus Corporation Compositions and methods for identifying biologically active molecules
US5593970A (en) 1990-06-11 1997-01-14 Biochem Pharma Inc. Heterocyclic anthracycline analogs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
US5391682A (en) 1991-07-03 1995-02-21 Kanebo, Ltd. Thermoplastic polyurethane elastomer, process for producing same, apparatus producing same and elastomer fibers made from same
US5283185A (en) 1991-08-28 1994-02-01 University Of Tennessee Research Corporation Method for delivering nucleic acids into cells
DK0604552T3 (da) 1991-09-18 1997-08-04 Affymax Tech Nv Fremgangsmåde til syntese af forskellige samlinger af oligomerer
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5604102A (en) 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5958883A (en) 1992-09-23 1999-09-28 Board Of Regents Of The University Of Washington Office Of Technology Animal models of human amyloidoses
ES2204910T3 (es) 1992-10-01 2004-05-01 The Trustees Of Columbia University In The City Of New York Bibliotecas quimicas combinatorias complejas codificadas con señales.
AU6014094A (en) 1992-12-02 1994-06-22 Baylor College Of Medicine Episomal vectors for gene therapy
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
CA2115900A1 (en) 1993-02-22 1994-08-23 Gerald W. Becker Pharmaceutical screens and antibodies
WO1995005853A1 (en) 1993-08-26 1995-03-02 The Regents Of The University Of California Method, compositions and devices for administration of naked polynucleotides which encode biologically active peptides
WO1995006407A1 (en) 1993-08-30 1995-03-09 The Regents Of The University Of California Novel component of amyloid in alzheimer's disease and methods for use of same
WO1995007707A1 (en) 1993-09-14 1995-03-23 Cytel Corporation Alteration of immune response using pan dr-binding peptides
AU703472B2 (en) 1993-11-02 1999-03-25 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5914349A (en) 1994-01-10 1999-06-22 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
WO1995030642A1 (en) 1994-05-06 1995-11-16 Pharmacopeia, Inc. Combinatorial dihydrobenzopyran library
US5505947A (en) 1994-05-27 1996-04-09 The University Of North Carolina At Chapel Hill Attenuating mutations in Venezuelan Equine Encephalitis virus
US5663046A (en) 1994-06-22 1997-09-02 Pharmacopeia, Inc. Synthesis of combinatorial libraries
EP1181937A3 (en) 1994-08-09 2004-02-04 Cytrx Corporation Novel vaccine adjuvant and vaccine
US5589154A (en) 1994-11-22 1996-12-31 Rutgers, The State University Of New Jersey Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
US5807741A (en) 1995-07-20 1998-09-15 Brown; Douglas Richard Neutralizing monoclonal antibody against botulinum neurotoxin serotype F
JP3830525B2 (ja) 1995-11-10 2006-10-04 サイトジェン，コーポレーション 組織横断輸送を強化するペプチドとその同定法および使用法
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
CA2242092C (en) 1996-12-03 2003-03-25 Northern Telecom Limited System connecting remote agents over standard telephone lines
DE69841122D1 (de) 1997-03-10 2009-10-15 Coley Pharm Gmbh Verwendung von nicht-methyliertem CpG Dinukleotid in Kombination mit Aluminium als Adjuvantien
WO1998059050A1 (en) 1997-06-25 1998-12-30 The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services Cloning of a gene mutation for parkinson's disease
WO1999006545A2 (en) 1997-08-01 1999-02-11 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation
US6923964B1 (en) 1997-12-02 2005-08-02 Neuralab Limited Active immunization of AScr for prion disorders
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
US6710226B1 (en) 1997-12-02 2004-03-23 Neuralab Limited Transgenic mouse assay to determine the effect of Aβ antibodies and Aβ Fragments on alzheimer's disease characteristics
US6787523B1 (en) 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
DK1063294T3 (da) 1998-02-09 2006-05-22 Boehringer Ingelheim Int DNA'er eller gener der deltager i Parkinsons sygdom
WO1999050300A1 (en) 1998-03-30 1999-10-07 The Trustees Of The University Of Pennsylvania Method of identifying, diagnosing and treating synuclein positive neurodegenerative disorders
DE69942274D1 (de) 1998-05-21 2010-06-02 Univ Tennessee Res Foundation Methoden zur amyloidentfernung mit anti-amyloid-antikörper
ES2255280T3 (es) * 1998-07-03 2006-06-16 Innogenetics N.V. Diagnostico diferencial de la neurodegeneracion.
US6184351B1 (en) 1998-09-25 2001-02-06 Amgen Inc. α-synuclein super-mutants accelerate α-synuclein aggregation
US6172122B1 (en) 1998-12-17 2001-01-09 The Lubrizol Corporation Stable emulsions from gelled overbased substrates with surfactants and aqueous liquids
US20040146521A1 (en) 1999-06-01 2004-07-29 Schenk Dale B. Prevention and treatment of synucleinopathic disease
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
WO2001006989A2 (en) 1999-07-27 2001-02-01 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
GB9924513D0 (en) 1999-10-15 1999-12-15 Novartis Ag Organic compounds
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
AU2001229592A1 (en) 2000-01-21 2001-07-31 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
US7276643B2 (en) 2000-02-18 2007-10-02 The Regents Of The University Of California Transgenic animals, cell lines derived therefrom, and methods for screening for anti-amyloidogenic agents
ME00183B (me) 2000-02-21 2011-02-10 Pharmexa As Novi postupak za deregulaciju amiloida
KR20080017471A (ko) 2000-02-21 2008-02-26 파멕사 에이/에스 아밀로이드의 하향-조절을 위한 신규한 방법
KR20020097241A (ko) 2000-05-04 2002-12-31 에이브이아이 바이오파마 인코포레이티드 스플라이스-영역 안티센스 조성물 및 방법
WO2002004482A1 (en) 2000-07-07 2002-01-17 Panacea Pharmaceuticals, Inc. Methods for preventing neural tissue damage and for the treatment of alpha-synuclein diseases
JP5362164B2 (ja) 2000-07-07 2013-12-11 バイオアークティック ニューロサイエンス アーベー アルツハイマー病の予防及び治療
TWI255272B (en) 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
AU2002222108A1 (en) * 2000-12-08 2002-06-18 Oxford Glycosciences (Uk) Ltd. Diagnosis and treatment of alzheimer's disease
US20020160394A1 (en) 2001-01-24 2002-10-31 Bayer Corporation Regulation of transthyretin to treat obesity
US6815175B2 (en) 2001-03-16 2004-11-09 Cornell Research Foundation, Inc. Anti-amyloid peptide antibody based diagnosis and treatment of a neurological disease or disorder
WO2003000714A2 (en) 2001-06-22 2003-01-03 Panacea Pharmaceuticals, Inc. Compositions and methods for preventing protein aggregation in neurodegenerative diseases
MY144532A (en) 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
AU2002357007A1 (en) 2001-11-21 2003-06-10 New York University SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID Beta, PRION PROTEIN, AMYLIN, Alpha-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
GB0203446D0 (en) 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
GB0216972D0 (en) 2002-07-22 2002-08-28 Univ Lancaster Peptides and peptide derivaties for the treatment of &-synuclein-related diseases
ATE429639T1 (de) 2002-09-30 2009-05-15 Univ Auburn Verfahren und isolierung zur selbstzusammenlagerung kleiner proteinpartikel aus blut und anderen biologischen materialien
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DK2361928T3 (en) 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
US20050203010A1 (en) 2003-11-14 2005-09-15 Atgen Co., Ltd. Novel peptides conferring environmental stress resistance and fusion proteins including said peptides
MX2007001679A (es) * 2004-08-09 2007-05-23 Elan Pharm Inc Prevencion y tratamiento de la enfermedad sinucleinopatica y amiloidogenica.
US20080300204A1 (en) 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
WO2007021255A1 (en) * 2005-08-09 2007-02-22 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
JP5558834B2 (ja) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease

Also Published As

Publication number Publication date
EP2118300B1 (en) 2015-05-27
PL2118300T3 (pl) 2015-11-30
CA2678963A1 (en) 2008-08-28
JP5558834B2 (ja) 2014-07-23
JP2010526028A (ja) 2010-07-29
PL2583978T3 (pl) 2016-07-29
US20100278814A1 (en) 2010-11-04
US8092801B2 (en) 2012-01-10
WO2008103472A3 (en) 2009-05-28
CA2678963C (en) 2018-05-01
EP2583978B1 (en) 2016-04-06
EP2583978A3 (en) 2013-09-11
WO2008103472A2 (en) 2008-08-28
EP2118300A4 (en) 2010-10-20
EP2118300A2 (en) 2009-11-18
EP2583978A2 (en) 2013-04-24

Similar Documents

Publication Publication Date Title
DK3067066T3 (da) Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
DK1793855T4 (da) Forebyggelse og behandling af synukleinopatisk og amyloidogenisk sygdom
DK2114447T3 (da) Forebyggelse og behandling af subkliniks pcvd
EP2182983A4 (en) TREATMENT OF AMYLOIDOGENIC DISEASES
DK2350416T4 (da) Multipel rude med mindst én antirefleksbehandling og anvendelse af antirefleksbehandling i multipel rude
BRPI0811142A2 (pt) Prevenção e tratamento de condições oculares associadas a complementos
DK2687223T4 (da) Påvisning og behandling af demens
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK2356093T3 (da) Carbazolforbindelser og terapeutiske anvendelser af forbindelserne
DK2115114T3 (da) Rengøringsenzymer og forebyggelse af ildelugt
BRPI0807495A2 (pt) Adjuvantes e métodos de emrpego dos mesmos
BRPI0822064A2 (pt) Dispositivos de imageamento fotoacústico e métodos de imageamento
PT2520295T (pt) Métodos para prevenir e tratar a mucosite
DK2185552T3 (da) Dipeptoid-prodrugs og anvendelse heraf
DK2294012T3 (da) Administration af et tarmrensemiddel og et antibiotika til behandlingen af tarmsygdom
DK3460056T3 (da) Terapeutiske nukleasesammensætninger og fremgangsmåder
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2222272T3 (da) Behandling af luftvejssygdom
DK2056807T3 (da) Behandling af inflammatoriske sygdomme
BRPI0816690A2 (pt) derivados 1-amino-alquilciclohexano para tratamento e a prevenção da perda da audição
BRPI0815551A2 (pt) Tratamento através de hucbc de doença beta-amiloide
DK2001556T3 (da) Thioninium-forbindelser og anvendelse deraf
DK2614832T3 (da) Diagnose og behandling af præeklampsi
DK2044223T3 (da) Diagnosticering og behandling af aldersrelateret makuladegeneration
DK2086213T3 (da) Billedlæseapparat og billeddannelseapparat